Close

Aerie (AERI) September volatility at 190 into 'successful' efficacy results of Phase 3 Roclatan trial

Go back to Aerie (AERI) September volatility at 190 into 'successful' efficacy results of Phase 3 Roclatan trial

Aerie Pharma (AERI) Enters $50M Equity Offering Sales Agreement

September 15, 2016 6:12 AM EDT

Aerie Pharma (NASDAQ: AERI) disclosed the following in a U.S. SEC filing on Thursday:

Item 1.01. Entry into Material Definitive Agreement.

On September 15, 2016, Aerie Pharmaceuticals, Inc. (the Company) entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., acting as agent, pursuant to which the Company may offer and sell, from time to time... More